undamentalytics Newsletter
Sign in

Pulse Biosciences, Inc. income statement

In fiscal 2025, Pulse Biosciences, Inc. reported revenue of $350,000, operating income of −$76.9m (a -21982.6% margin) and net income of −$72.8m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0110001
Cost of revenue02120011
Gross profit0−1−1100−00
Research and development26292128324552
Selling, general and administrative————243231
General and administrative16191416———
Operating income−50−63−58−44−56−77−83
Net interest income0——————
Income before tax−50−64−59−425473—
Income tax000000—
Net income−50−64−59−42−54−73−80
Diluted EPS−$2.14−$2.28————−$1.18
Diluted shares (average)23m28m34m50m58m67m68m
EBITDA−50−63−57−43−56−77−83

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IMDX vs PLSEICU vs PLSECODX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Pulse Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pulse Biosciences, Inc.